mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death

Oncogene. 2023 Jun;42(24):2007-2016. doi: 10.1038/s41388-023-02706-6. Epub 2023 May 3.

Abstract

Myc is a key driver of colorectal cancer initiation and progression, but remains a difficult drug target. In this study, we show that mTOR inhibition potently suppresses intestinal polyp formation, regresses established polyps, and prolongs lifespan of APCMin/+ mice. Everolimus in diet strongly reduces p-4EBP1, p-S6, and Myc levels, and induces apoptosis of cells with activated β-catenin (p-S552) in the polyps on day 3. The cell death is accompanied by ER stress, activation of the extrinsic apoptotic pathway, innate immune cell recruitment, and followed by T-cell infiltration on day 14 persisting for months thereafter. These effects are absent in normal intestinal crypts with physiologic levels of Myc and a high rate of proliferation. Using normal human colonic epithelial cells, EIF4E S209A knockin and BID knockout mice, we found that local inflammation and antitumor efficacy of Everolimus requires Myc-dependent induction of ER stress and apoptosis. These findings demonstrate mTOR and deregulated Myc as a selective vulnerability of mutant APC-driven intestinal tumorigenesis, whose inhibition disrupts metabolic and immune adaptation and reactivates immune surveillance necessary for long-term tumor control.

MeSH terms

  • Animals
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / metabolism
  • Everolimus* / pharmacology
  • Humans
  • Immunogenic Cell Death
  • Mice
  • Mice, Knockout
  • Signal Transduction
  • TOR Serine-Threonine Kinases / metabolism
  • beta Catenin / metabolism

Substances

  • Everolimus
  • TOR Serine-Threonine Kinases
  • beta Catenin